Chanping Liang, MD
Ophthalmology · Shreveport, LANPI 1558386441
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 338 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 38.0% of the total. 2025 is the largest year on record at $3,623, 2.8 times the $1,272 reported in 2019. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 338 payments — averaging $43.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Sight Sciences, Inc.$3K
- Alcon$3K
- Glaukos Corporation$1K
- Bausch & Lomb Americas Inc.$842
- Amgen$401
- plus $1K from 12 others
What the payments were for
- Food & beverage$14,705100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 125 | $5,594 |
| Sight Sciences, Inc. | 91 | $2,668 |
| Alcon | 55 | $2,623 |
| Glaukos Corporation | 11 | $1,170 |
| Bausch & Lomb Americas Inc. | 22 | $842 |
| Amgen(2 entities) | 8 | $401 |
| Dompe US, Inc. | 5 | $320 |
| Aerie Pharmaceuticals, Inc. | 9 | $257 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $200 |
| Alimera Sciences, Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Biotissue Holdings Inc. | 1 | $105 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $100 |
| Topcon Healthcare, Inc. | 1 | $86 |
| Ivantis, Inc | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| NEW World Medical,inc. | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$2,271
- DURYSTA$827
- OMNI(R) SURGICAL SYSTEM (US)$634
- iStent inject W$446
- Hydrus Microstent$400
- Centurion$381
- Rhopressa$374
- Rocklatan$374
- VYZULTA$344
- Oxervate$258
- LUMIGAN$250
- MIEBO$250
- XEN$246
- TEPEZZA$235
- Tecnis IOL$200
- iStent inject Trabecular Micro-Bypass Stent System$156
- Unity$147
- iStent infinite Trabecular Micro-Bypass System Model iS3$144
- iDose$138
- Voyager DSLT$134
How this compares
$14,705 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 121 | $59,293 |
| RocklatanNetarsudil Mesylat/Latanoprost | 55 | $29,900 |
| RhopressaNetarsudil Mesylate | 49 | $27,945 |
| Prednisolone Acetate | 231 | $14,195 |
| Brimonidine Tartrate | 441 | $12,202 |
| CombiganBrimonidine Tartrate/Timolol | 35 | $11,233 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 61 | $10,519 |
| Latanoprost | 1,155 | $9,783 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 533 | $7,934 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $4,570 |
| Dorzolamide Hcl | 209 | $4,349 |
| Acetazolamide | 56 | $3,845 |
| VyzultaLatanoprostene Bunod | 11 | $2,916 |
| Timolol Maleate | 181 | $2,836 |
| Travoprost | 13 | $2,357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $5,594 | $70,526156 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $257 | $57,844104 claims |
| AlconSimbrinza | $2,623 | $4,57020 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $842 | $2,91611 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $200 | $1,43215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Shreveport
- Wyche ColemanShreveport$35K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
- Claude BundrickShreveport$12K
- Bryan LuskShreveport$10K
- Arthur KavanaughShreveport$7K
- Ann GuyShreveport$6K
- Jeffrey LuskShreveport$5K
- John CarmodyShreveport$5K
- Blake WilliamsonBaton Rouge$443K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.